Catalyst Pharmaceuticals stock rises 2.17% and outperforms rivals

10 articles · Updated · MarketWatch · May 1

Shares closed at $28.74 on Friday, beating Johnson & Johnson, Pfizer and Abbott Laboratories in a mixed US market session.
The gain ended a two-day losing streak as the Nasdaq Composite rose 0.89% to 25,114.44 while the Dow Jones Industrial Average fell 0.31% to 49,499.27.
Catalyst remains 11.73% below its 52-week high of $32.56 reached on 27 April, and trading volume of 1.4 million was slightly below its 50-day average.

Despite bullish analyst ratings and strong financials, is Catalyst Pharmaceuticals truly undervalued, or are market risks being overlooked?

With Firdapse's patent threats looming, what acquisitions or innovations might Catalyst pursue to secure its future beyond rare disease mainstays?